API manufacturers
Active pharmaceutical ingredient sites aligning systems with WHO TRS 957 Annex 2 and export customer expectations.
- TRS 957
- API
- Validation
Align pharmaceutical quality systems with WHO TRS GMP expectations, update SMF and SOP records, and prepare COPP (CPP) application documentation. NQSC supports gap analysis, validation evidence, mock audit readiness, and CDSCO coordination. NQSC does not issue certificates or conduct authority inspections.
WHO-GMP and COPP readiness
Which GMP pathway applies?
Who needs this
NQSC supports API and finished dosage manufacturers, export units, Schedule M upgrade sites, CMOs, and teams preparing for authority GMP inspection.
Active pharmaceutical ingredient sites aligning systems with WHO TRS 957 Annex 2 and export customer expectations.
Formulation sites preparing WHO TRS 986 Annex 2 records, batch documentation, and product quality review.
Sites filing for Certificate of Pharmaceutical Product (CPP/COPP) under the WHO Certification Scheme through CDSCO.
Indian licensed sites strengthening pharmaceutical quality systems, validation, and data integrity under Schedule M.
QA teams preparing self-inspection programmes, CAPA closure, and mock audits before authority GMP inspection.
CMOs and loan-license units aligning SMF, batch records, and principal MAH documentation requirements.
Compare pathways
Domestic licensed manufacturing and export COPP filing follow different evidence sets. WHO Prequalification is a separate dossier and inspection path for listed procurement products.
Best for: licensed Indian manufacturing sites subject to state or CDSCO GMP inspections.
Relevant forms
Best for: export markets that rely on the WHO Certification Scheme and CDSCO-issued COPP.
Relevant forms
Documentation
Grouped for gap review before COPP filing or authority GMP inspection.
Note: Final document scope is confirmed after reviewing site layout, product list, manufacturing license scope, and target COPP or inspection pathway.
Process
A structured process for annex scoping, gap analysis, documentation updates, mock audit readiness, and COPP application support.
Confirm API vs finished dosage, sterile vs non-sterile scope, and applicable WHO TRS GMP annex before documentation work.
Review site systems against WHO GMP expectations and Schedule M requirements where the site holds an Indian manufacturing license.
Update site master file, core procedures, batch manufacturing records, and quality system evidence.
Close validation, qualification, training, and self-inspection findings with objective evidence.
Run pre-inspection reviews, document trails, and CAPA closure checks before authority inspection.
Support COPP application documentation and responses to CDSCO or state authority queries after submission.
How NQSC helps
NQSC supports TRS mapping, SMF and SOP updates, validation evidence, self-inspection programmes, COPP dossier structuring, and pre-inspection coordination.
Map site activity to WHO TRS GMP texts (TRS 986, TRS 957, TRS 1044, TRS 1060) and Schedule M where the site is India-licensed.
Structure site master file, quality manual, SOPs, batch records, and forms aligned to site scope and product type.
Support validation master plans, IQ/OQ/PQ protocols, utility qualification, and equipment qualification records.
Help plan self-inspections, deviation handling, CAPA workflows, and management review evidence.
Structure COPP (CPP) application records, product lists, labeling references, and CDSCO submission checklists.
Support mock audits, document retrieval readiness, and responses to authority queries after filing.
Avoid delays
Issues NQSC often sees during WHO GMP gap reviews and COPP application preparation.
Domestic Schedule M compliance alone does not replace a COPP dossier review, SMF alignment, and export inspection readiness.
Site master file layout, flows, or equipment lists not aligned with actual manufacturing areas and operations.
Validation master plan missing, incomplete, or not linked to critical systems, utilities, and processes.
Weak linkage between raw materials, intermediates, finished batches, and distribution records.
Corrective actions closed without verifying recurrence prevention or systemic root cause closure.
ISO 9001 or other ISO certificates treated as proof of WHO GMP compliance without authority GMP verification.
Client trust
Feedback from teams supported across GMP documentation, audit readiness, quality system upgrades, and regulatory coordination.
ISO · CE · CDSCO“Excellent support throughout certification activities, including ISO, CE marking and CDSCO submissions.”
CDSCO · Manufacturing“Fast and accurate service.”
Regulatory Support“We are fully satisfied with the services provided by NQSC.”
Selected clients supported by NQSC
FAQ
Short answers on WHO TRS GMP texts, COPP, Schedule M, inspections, and how NQSC supports your pathway.
WHO publishes GMP in the Technical Report Series (TRS). TRS 986 Annex 2 covers main principles for pharmaceutical products. Additional annexes address APIs (TRS 957), sterile products (TRS 1044), excipients (TRS 1060), and quality risk management (TRS 981). NQSC supports documentation aligned to the annex that matches your site scope.
The Certificate of Pharmaceutical Product (often called COPP or CPP) is the primary document in the WHO Certification Scheme on the quality of pharmaceutical products moving in international commerce. Importing authorities use it to assess marketing status and manufacturer GMP compliance in the exporting country.
CDSCO guidance describes document scrutiny and joint inspection for grant or revalidation of COPPs. Inspections are conducted by national regulatory authorities, not by NQSC. WHO Prequalification runs separate GMP inspections for sites linked to prequalification dossiers.
Schedule M under the Drugs and Cosmetics Rules is the mandatory GMP framework for licensed manufacturing in India. COPP and WHO-type export evidence follow the WHO Certification Scheme and TRS GMP texts. Revised Schedule M is closer to WHO expectations, but export filing still needs a separate COPP readiness review.
WHO Prequalification assesses specific products for UN and partner procurement, including dossier review and GMP inspection of submitted API or finished product sites. COPP is issued by the national authority under the Certification Scheme. The two pathways serve different purposes and are not interchangeable.
No. NQSC provides documentation, gap analysis, and inspection readiness support. Certificates and inspection outcomes depend on site performance and findings from the competent authority or WHO Prequalification where applicable.
Share dosage forms, API vs finished product scope, sterile or non-sterile operations, target markets, and inspection timeline. NQSC will outline GMP gap analysis and documentation priorities.
Documentation support only. Certificates and inspections are conducted by competent authorities.